Showing results (71-80 of 89) with videos related to

Sort By:
Pageof 9
Journal of Translational Medicine|November 26, 2024
Exploring the role of PARP1 inhibition in enhancing antibody-drug conjugate therapy for acute leukemias: insights from DNA damage response pathway interactionsAndrea Ghelli Luserna di Rorà, Mouna Jandoubi, Antonella Padella, et al.
Blood|March 14, 2007
ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemiaChiara Gregorj, Maria R Ricciardi, Maria T Petrucci, et al.
Internal and Emergency Medicine|January 15, 2015
Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemiaAndrea Piccin, Michael Steurer, Manfred Mitterer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 2, 2018
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana LinfomiJacopo Olivieri, Federico Mosna, Matteo Pelosini, et al.
Blood Advances|October 25, 2024
Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OSThomas Cluzeau, Fabio Guolo, Edmond Chiche, et al.
Blood Advances|February 10, 2025
Posttransplant cyclophosphamide as GVHD prophylaxis in patients receiving mismatched unrelated HCT: the PHYLOS trialAnna Maria Raiola, Benedetto Bruno, Antonio Maria Risitano, et al.
Annals of Hematology|August 26, 2025
Pegaspargase administration and tolerability in patients aged 55 years or older with acute lymphoblastic leukemia treated with the LAL1913 program. A subanalysis of the Campus ALL groupDavide Lazzarotto, Anna Maria Testi, Matteo Fanin, et al.
Bone Marrow Transplantation|June 2, 2025
Outcomes of allogeneic stem cell transplant in adult Philadelphia negative acute lymphoblastic leukemia patients treated with the pediatric-inspired GIMEMA 1913 protocol. A Campus ALL studyGianluca Cavallaro, Davide Lazzarotto, Chiara Pavoni, et al.
Cancer|March 22, 2025
INO-CD22: A multicenter, real-world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemiaCristina Papayannidis, Elisabetta Petracci, Patrizia Zappasodi, et al.
Annals of Hematology|May 24, 2025
Matching-adjusted indirect comparison of CPX- 351 in secondary Acute Myeloid Leukemia between the registrative trial and a real-life studyLuana Fianchi, Alfonso Piciocchi, Fabio Guolo, et al.
Pageof 9